4BIO Capital Drives Investment in Innovative Therapy
March Biosciences is making significant strides in the development of its breakthrough autologous chimeric antigen receptor T-cell (CAR-T) therapy known as MB-105. This innovative treatment is aimed at addressing relapsed and refractory CD5 positive T-cell lymphoma, a condition that has been challenging for many patients and healthcare providers.
Funding Expansion for March Biosciences
Recently, 4BIO Capital led a successful financing round, amassing $28.4 million, which included strong contributions from Mission BioCapital and several esteemed investors such as KdT Ventures, Alexandria Venture Investments, Volnay Therapeutics, Modi Ventures, and Mansueto Investments. This round was notably oversubscribed, signaling robust confidence from the investment community regarding the potential of March Bio's offerings.
The Journey of March Biosciences
Founded as a spinout from the Center for Cell and Gene Therapy, which involves prestigious institutions like Baylor College of Medicine, March Biosciences is focused on exploiting advanced cell and gene therapeutic strategies. Their lead candidate, MB-105, is designed to tackle the challenges presented by T-cell fratricide while ensuring effective targeting of CD5 positive tumor cells. Early clinical trials have shown promising results, with MB-105 exhibiting a favorable safety profile and durable remissions in patients previously ineffectively treated.
Significance of the New Funding
The recent investment will primarily focus on advancing the development of MB-105, particularly as the company prepares to enter Phase 2 clinical trials. These trials aim to expand upon the initial data gathered from Phase 1, utilizing the funds to refine manufacturing processes and enhance treatment efficacy. Markedly, the Phase 2 trials are expected to kick off shortly, showcasing the rapid progress being made in this vital therapeutic area.
Expert Insights on the Advantages of CAR-T Therapy
The advancements in CAR-T therapy have sparked optimism within the oncology community, especially for patients suffering from hard-to-treat cancers. Owen Smith, a partner at 4BIO Capital, highlighted how the innovative approach of March Bio not only represents a significant step forward in treating T-cell cancers but also offers new hope for patients facing bleak prognoses. The targeted mechanism of MB-105 is set to change the dynamics of treatment options available, filling a crucial gap in personalized cancer therapy.
Future Directions for March Bio
Looking ahead, March Biosciences is not just focused on its flagship therapy. The financial support from this funding round will also enable the ongoing development of additional pipeline products that remain undisclosed at this time. This forward-thinking strategy reinforces the company's dedication to substantially improving patient outcomes for those afflicted by aggressive cancers.
A Commitment to Revolutionary Therapies
Sarah Hein, Co-Founder and CEO of March Biosciences, shared her vision by stating that the financing provides the essential capital needed to advance their groundbreaking CAR-T therapy into a Phase 2 trial. With the backing from 4BIO Capital and others, March is poised to not only enhance its leading project but also expand its portfolio to meet the broader needs of patients. This commitment underlines their goal to transform the treatment landscape for those dealing with challenging cancers.
Frequently Asked Questions
What is the purpose of March Biosciences' MB-105 therapy?
MB-105 is designed to treat relapsed and refractory CD5 positive T-cell lymphoma, offering a new hope for patients with limited treatment options.
Who led the recent financing round for March Biosciences?
The financing round was led by 4BIO Capital along with participation from Mission BioCapital and several other investors.
What are the future plans for MB-105?
March Biosciences plans to advance MB-105 into Phase 2 clinical trials to build on the promising results from Phase 1 trials.
How does CAR-T therapy work?
CAR-T therapy involves engineering a patient's own T-cells to better recognize and attack cancer cells, providing a targeted treatment method.
What other projects are March Biosciences working on?
In addition to MB-105, March is developing additional pipeline products, which have not yet been disclosed to the public.
